^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    IMA401

    i
    Other names: IMA401, IMA 401, IMA-401
    Associations

    News

    Trials
    Company:
    Immatics
    Drug class:
    TCR modulator, MAGE-A4 inhibitor, MAGE-A8 inhibitor
    Related drugs:
    Associations

    News

    Trials
    11d
    MAGE-A4/MAGE-A8-targeted TCR-based bispecific T cell engager in recurrent and/or refractory solid tumors: a phase 1 trial. (PubMed, Nat Med)
    No further DLTs occurred in the RP2D range with dexamethasone premedication. These findings show that the bispecific TCER platform has a manageable safety profile with mostly transient adverse events and promising antitumor activity at the RP2D of IMA401 with or without pembrolizumab. ClinicalTrials.gov identifier: NCT05359445 .
    P1 data • Journal • First-in-human
    |
    HLA-A (Major Histocompatibility Complex, Class I, A) • MAGEA4 (Melanoma antigen family A, 4)
    |
    Keytruda (pembrolizumab) • dexamethasone • IMA401
    2ms
    IMA401-101: IMA401 TCER® in Recurrent and/or Refractory Solid Tumors, Alone or in Combination With a Checkpoint Inhibitor (clinicaltrials.gov)
    P1, N=95, Active, not recruiting, Immatics Biotechnologies GmbH | Recruiting --> Active, not recruiting | Trial primary completion date: Nov 2025 --> Mar 2026
    Enrollment closed • Trial primary completion date • Checkpoint inhibition • First-in-human
    |
    MAGEA4 (Melanoma antigen family A, 4)
    |
    Keytruda (pembrolizumab) • IMA401
    over1year
    IMA401-101: IMA401 TCER® in Recurrent and/or Refractory Solid Tumors, Alone or in Combination With a Checkpoint Inhibitor (clinicaltrials.gov)
    P1, N=95, Recruiting, Immatics Biotechnologies GmbH | N=50 --> 95 | Trial completion date: Nov 2027 --> Dec 2029
    Enrollment change • Trial completion date • Checkpoint inhibition
    |
    MAGEA4 (Melanoma antigen family A, 4)
    |
    Keytruda (pembrolizumab) • IMA401
    over2years
    IMA401 TCER® in Recurrent and/or Refractory Solid Tumors (clinicaltrials.gov)
    P1, N=50, Recruiting, Immatics Biotechnologies GmbH | Phase classification: P1a/1b --> P1
    Phase classification
    |
    MAGEA4 (Melanoma antigen family A, 4)
    |
    MAGEA4 expression • MAGEA4 overexpression
    |
    IMA401
    4years
    IMA401 TCER® in Recurrent and/or Refractory Solid Tumors (clinicaltrials.gov)
    P1a/1b, N=50, Recruiting, Immatics Biotechnologies GmbH | Not yet recruiting --> Recruiting
    Enrollment open
    |
    MAGEA4 (Melanoma antigen family A, 4)
    |
    MAGEA4 expression
    |
    IMA401
    4years
    IMA401 TCER® in Recurrent and/or Refractory Solid Tumors (clinicaltrials.gov)
    P1a/1b, N=50, Not yet recruiting, Immatics Biotechnologies GmbH
    New P1 trial
    |
    MAGEA4 (Melanoma antigen family A, 4)
    |
    MAGEA4 expression
    |
    IMA401